Flamel Technologies SA News

December 18, 2009 Flamel Technologies trading at $7.67 on a volume of 2,300 shares Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection LYON, France, Dec 18, 2009 -- Flamel Technologies today announced the initiation of a Phase 2a clinical trial of ...

Platforms aren't just for acrobatic moves before splashing into the pool or '70s night at the disco.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/04/09, Flamel Technologies expects to release its financial results for the third quarter of 2009 the morning of November 16th, before the market opening.

LYON, France-- --Flamel Technologies expects to release its financial results for the third quarter of 2009 the morning of November 16th, before the market opening.

Pasadena, CA - 09/19/09 - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Flamel Technologies today announced that Stephen Willard, Flamel's chief executive officer, will be presenting at the UBS Global Life Sciences Conference in New York.

DEERFIELD, Ill. & LYON, France-- --Baxter International Inc. and Flamel Technologies, SA announced today that they have entered into agreement to formulate controlled release applications of blood clotting factor replacement therapies using Flamela s MedusaA Technology.

Jun 25, 2009 - Flamel Technologies S.A. today announced that it has entered into two new feasibility agreements to apply its Medusa platform with two additional companies.

The election of each member of the Board of Directors of the Company for a further one-year term was approved by holders of more than 99% of the Companya s shares.

The key technologies of the company includes Medusa nanoparticulate technology, Micropump technology and Trigger-Lock technology.